{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:13:28Z","timestamp":1780917208739,"version":"3.54.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["CAN 2018\/362"],"award-info":[{"award-number":["CAN 2018\/362"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bmcl.2025.130456","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T15:51:14Z","timestamp":1762012274000},"page":"130456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Strengths and limitations of Ba\/F3 cells in modelling FLT3-driven AML resistance"],"prefix":"10.1016","volume":"131","author":[{"given":"Jingmei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8696-3104","authenticated-orcid":false,"given":"Ran","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bmcl.2025.130456_b1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.hoc.2017.04.005","article-title":"Mechanisms of resistance to FLT3 inhibitors and the role of the bone marrow microenvironment","volume":"31","author":"Ghiaur","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130456_b2","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00992-1","article-title":"Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia","volume":"13","author":"Gebru","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130456_b3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10585-022-10189-0","article-title":"Resistance to targeted therapies in acute myeloid leukemia","volume":"40","author":"Mecklenbrauck","year":"2022","journal-title":"Clin Exp Metastasis"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130456_b4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.20517\/cdr.2022.130","article-title":"How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?","volume":"6","author":"Perrone","year":"2023","journal-title":"Cancer Drug Resist"},{"issue":"8","key":"10.1016\/j.bmcl.2025.130456_b5","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1021\/acs.jmedchem.9b00223","article-title":"Identification of Pyrrolo[2,3]pyrimidine-based derivatives as potent and orally effective fms-like tyrosine receptor kinase 3 (FLT3) inhibitors for treating acute myelogenous leukemia","volume":"62","author":"Yuan","year":"2019","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130456_b6","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood-2017-05-786657","article-title":"A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations","volume":"131","author":"Yamaura","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130456_b7","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1021\/acs.jmedchem.7b01261","article-title":"Discovery of 4-((7-]pyrimidin-4-yl)amino)-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-kinase inhibitor with potentially high efficiency against acute myelocytic leukemia","volume":"61","author":"Wang","year":"2018","journal-title":"J Med Chem"},{"issue":"19","key":"10.1016\/j.bmcl.2025.130456_b8","doi-asserted-by":"crossref","first-page":"14664","DOI":"10.1021\/acs.jmedchem.1c01196","article-title":"Discovery of a potent FLT3 inhibitor (LT-850-166) with the capacity of overcoming a variety of FLT3 mutations","volume":"64","author":"Wang","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130456_b9","article-title":"Resistance to FLT3 inhibitors involves different molecular mechanisms and reduces new DNA synthesis","volume":"41","author":"Yang","year":"2025","journal-title":"Biochem Biophys Rep"},{"key":"10.1016\/j.bmcl.2025.130456_b10","doi-asserted-by":"crossref","first-page":"108424","DOI":"10.1016\/j.bioorg.2025.108424","article-title":"Inhibition of FLT3-induced signalling in refractory acute myeloid leukaemia","volume":"160","author":"Yang","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmcl.2025.130456_b11","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12935-021-01856-5","article-title":"Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib","volume":"21","author":"Yang","year":"2021","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130456_b12","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-023-03000-x","article-title":"Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemia","volume":"23","author":"Yang","year":"2023","journal-title":"Cancer Cell Int"},{"issue":"23","key":"10.1016\/j.bmcl.2025.130456_b13","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1073\/pnas.85.23.9312","article-title":"Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr\/abl protein","volume":"85","author":"Daley","year":"1988","journal-title":"Proc Nal. Acad Sci USA"},{"key":"10.1016\/j.bmcl.2025.130456_b14","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bmcl.2025.130456_b15","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1158\/0008-5472.CAN-07-0345","article-title":"Rational drug redesign to overcome drug resistance in cancer therapy: Imatinib moving target","volume":"67","author":"Fern\u00e1ndez","year":"2007","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.bmcl.2025.130456_b16","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/prot.25368","article-title":"The molecular mechanism behind resistance of the kinase FLT3 to the inhibitor quizartinib","volume":"85","author":"Friedman","year":"2017","journal-title":"Proteins"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130456_b17","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.bbagen.2019.01.011","article-title":"The catalytic activity of Abl1 single and compound mutations: Implications for the mechanism of drug resistance mutations in chronic myeloid leukaemia","volume":"1863","author":"Georgoulia","year":"2019","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"20","key":"10.1016\/j.bmcl.2025.130456_b18","doi-asserted-by":"crossref","first-page":"10025","DOI":"10.1073\/pnas.1819430116","article-title":"Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations","volume":"116","author":"Ikemura","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"issue":"49","key":"10.1016\/j.bmcl.2025.130456_b19","doi-asserted-by":"crossref","first-page":"6727","DOI":"10.1039\/D0CC02164D","article-title":"Is breaking of a hydrogen bond enough to lead to drug resistance?","volume":"56","author":"D\u00e1vila-Rodr\u00edguez","year":"2020","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.bmcl.2025.130456_b20","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1111\/febs.15209","article-title":"Deciphering the molecular mechanism of FLT3 resistance mutations","volume":"287","author":"Georgoulia","year":"2020","journal-title":"FEBS J"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130456_b21","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-58877-9","article-title":"Improvement in predicting drug sensitivity changes associated with protein mutations using a molecular dynamics based alchemical mutation method","volume":"10","author":"Ono","year":"2020","journal-title":"Sci Rep"},{"issue":"46","key":"10.1016\/j.bmcl.2025.130456_b22","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111451118","article-title":"Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance","volume":"118","author":"Lyczek","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2025.130456_b23","doi-asserted-by":"crossref","DOI":"10.1002\/wcms.1563","article-title":"Computational studies of protein-drug binding affinity changes upon mutations in the drug target","volume":"12","author":"Friedman","year":"2022","journal-title":"WIREs Comput Mol Sci"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130456_b24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188666","article-title":"The molecular mechanisms behind activation of FLT3 in acute myeloid leukemia and resistance to therapy by selective inhibitors","volume":"1877","author":"Friedman","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"8","key":"10.1016\/j.bmcl.2025.130456_b25","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1039\/D2CP05549J","article-title":"Resistance to a tyrosine kinase inhibitor mediated by changes to the conformation space of the kinase","volume":"25","author":"Freire","year":"2023","journal-title":"Phys Chem Chem Phys"},{"key":"10.1016\/j.bmcl.2025.130456_b26","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2025.103158","article-title":"Resistance mutations, drug binding and drug residence times","volume":"95","author":"Friedman","year":"2025","journal-title":"Curr Opin Struct Biol"},{"issue":"5","key":"10.1016\/j.bmcl.2025.130456_b27","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1158\/1535-7163.MCT-21-0317","article-title":"The irreversible FLT3 inhibitor FF-10101 is active against a diversity of FLT3 inhibitor resistance mechanisms","volume":"21","author":"Ferng","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.bmcl.2025.130456_b28","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/leu.2013.14","article-title":"The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and sunitinib","volume":"27","author":"Albers","year":"2013","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.bmcl.2025.130456_b29","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.bmcl.2025.130456_b30","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/bloodadvances.2021006489","article-title":"Molecular profile of FLT3-mutated relapsed\/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib","volume":"6","author":"Smith","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.bmcl.2025.130456_b31","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.3324\/haematol.2012.069781","article-title":"The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220","volume":"97","author":"Pauwels","year":"2012","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130456_b32","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1182\/bloodadvances.2019000919","article-title":"Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations","volume":"4","author":"Tarver","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.bmcl.2025.130456_b33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082059","article-title":"Drug resistance missense mutations in cancer are subject to evolutionary constraint","volume":"8","author":"Friedman","year":"2013","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.bmcl.2025.130456_b34","doi-asserted-by":"crossref","first-page":"15540","DOI":"10.1021\/acs.jmedchem.2c01361","article-title":"Targeting gatekeeper mutations for kinase drug discovery","volume":"65","author":"Zhou","year":"2022","journal-title":"J Med Chem"},{"issue":"Supplement_1","key":"10.1016\/j.bmcl.2025.130456_b35","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2019-124632","article-title":"FF-10101 retains potent inhibitory activities against resistant mutations to FLT3 inhibitors, newly identified in random mutagenesis screens","volume":"134","author":"Ishikawa","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bmcl.2025.130456_b36","first-page":"6026","article-title":"Overexpression of ABCB1 confers resistance to FLT3 inhibitor FN-1501 in cancer cells: in vitro and in vivo characterization","volume":"13","author":"Zhang","year":"2023","journal-title":"Am J Cancer Res"},{"issue":"6","key":"10.1016\/j.bmcl.2025.130456_b37","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1021\/acs.jmedchem.0c01851","article-title":"FLT3 inhibitors in acute myeloid leukemia: Challenges and recent developments in overcoming resistance","volume":"64","author":"Wang","year":"2021","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130456_b38","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbac203","article-title":"Exploring the kinase-inhibitor fragment interaction space facilitates the discovery of kinase inhibitor overcoming resistance by mutations","volume":"23","author":"Wang","year":"2022","journal-title":"Briefings Bioinf"},{"key":"10.1016\/j.bmcl.2025.130456_b39","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebiom.2019.01.019","article-title":"Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance","volume":"41","author":"Okada","year":"2019","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130456_b40","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/cas.15263","article-title":"Utility of the Ba\/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer","volume":"113","author":"Koga","year":"2022","journal-title":"Cancer Sci"},{"key":"10.1016\/j.bmcl.2025.130456_b41","doi-asserted-by":"crossref","first-page":"11746","DOI":"10.18632\/oncotarget.7459","article-title":"Drug resistance in cancer: molecular evolution and compensatory proliferation","volume":"7","author":"Friedman","year":"2016","journal-title":"Oncotarget"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25003658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25003658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T10:35:48Z","timestamp":1780914948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25003658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":41,"alternative-id":["S0960894X25003658"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130456","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strengths and limitations of Ba\/F3 cells in modelling FLT3-driven AML resistance","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130456","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"130456"}}